Oslo

• A randomized clinical two-arm trial comparing inflammation and cystoid macular edema for the medication regimens postoperative topical NSAID … Recruiting
  2023-510091-31-00 6 2022-12-02 Fuchs dystrophy
• A study of tucatinib with trastuzumab and mFOLFOX6 versus standard of care treatment in first-line HER2+ metastatic colorectal cancer Recruiting
  2024-514180-25-00 5 2022-11-21 unresectable or metastatic HER2+ colorectal cancer
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination … Recruiting
  2023-503442-30-00 5 2022-10-14 Multiple Myeloma
• EVIDENT Recruiting
  2023-510092-62-00 4 2022-09-27 Colorectal cancer
• Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Dia … Recruiting
  2023-510384-36-00 5 2022-09-13 Newly Diagnosed Multiple Myeloma
• Studying Conditioning Regimen In Pediatric Transplantation -AML Recruiting
  2023-505512-37-00 5 2022-06-07 Acute Myeoloid Leukemia
• Sotorasib in advanced KRAS G12C-mutated non-small cell lung cancer patients with comorbidities (SOLUCOM) Recruiting
  2023-503174-20-00 4 2022-05-30 KRAS G12C-mutated non-small cell lung cancer
• NeoAdjuvant PErsonalized therapy in Estrogen Receptor positive breast cancer (NAPEER) - An open label phase II trial of endocrine treatment … Recruiting
  2023-510093-13-00 4 2022-05-11 Patients with hormone receptor positive HER2 negative breast cancer.
• A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectabl … Recruiting
  2023-506891-28-00 5 2022-05-02 The target population of interest in this study is participants with l
• Pre- vs. postoperative thromboprophylaxis for liver resection – a prospective, multicentre, randomized controlled trial (PREPOSTEROUS trial) Recruiting
  2024-519726-20-00 6 2022-03-17 Liver surgery
• A study to evaluate long-term Infigratinib in children with Achondroplasia Recruiting
  2024-513857-55-00 4 2022-02-08 Achondroplasia
• Efficacy of Hyperbaric oxygen in addition to standard treatment for acute sudden deafness Recruiting
  2024-510798-84-00 10 2022-01-28 Idiopathic sudden sensorineural hearing loss (ISSNHL)
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting
  2023-505438-85-00 5 2022-01-12 Acute myocardial infarction (AMI)
• SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years. Recruiting
  2024-510578-25-00 5 2021-11-05 Histologically proven high-risk medulloblastoma, with any of the curre
• HARBOR: Study of BLU-263 for Indolent Systemic Mastocytosis Recruiting
  2024-516728-32-00 10 2021-10-29 Indolent Systemic Mastocytosis and SSM
• A Phase 1/2 Trial of the Synthetic Cannabinoid ART27.13 in Patients with Cancer Anorexia and Weight Loss Recruiting
  2024-518177-33-00 7 2021-10-01 Cancer Anorexia
• OPTIMISE Recruiting
  2023-509814-12-00 4 2021-09-22 Colorectal cancer with metastasis
• NMDSG-14B2 Recruiting
  2024-511651-17-00 4 2021-09-21 Myelodysplastic syndrome
• The SABLe study Recruiting
  2024-512276-35-00 4 2021-08-09 Multiple Myeloma
• Improving public cancer care by implementing precision medicine in Norway Recruiting
  2023-507894-16-00 4 2021-04-01 Cancer
• Isatuximab in combination with novel agents in RRMM – Master protocol and control arm Recruiting
  2024-514988-25-00 9 2021-03-31 Cancer
• Isatuximab in combination with SAR445761 (belumosudil) and dexamethasone in relapsed or refractory multiple myeloma Recruiting
  2024-514992-16-00 9 2021-03-31 Cancer
• Isatuximab in combination with evorpacept and dexamethasone in RRMM Recruiting
  2024-514993-38-00 9 2021-03-31 Cancer
• Sequential neoadjuvant ifosfamide and doxorubicin in localized high-grade soft tissue sarcoma of extremities and trunk wall Recruiting
  2023-510185-27-00 4 2021-03-01 Patients with high-grade soft tissue sarcoma of the extremities and tr

Showing 241–264 of 508 trials